Three decades of clinical follow-up in 271 women with hyperprolactinaemia; macroprolactinaemia should be considered [2]

Clinical Endocrinology

Volumn 64, Issue 2, 2006, Pages 226-

  Fahie Wilson, Michael N ^a   Ahlquist, James A ^a   Ellis, Andrew R ^b  

^a SOUTHEND HOSPITAL   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; IMMUNOASSAY; LABORATORY; LETTER; MENSTRUATION; PATIENT; PRIORITY JOURNAL;

FEMALE; HUMANS; HYPERPROLACTINEMIA; PROLACTIN;

EID: 33645028948     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02431.x     Document Type: Letter

References (5)

1. Berinder K. Stackenast I. Akre O. Linden Hirschberg A. Hulting A.-L. 2005 Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up Clinical Endocrinology 63 450 455
2. Fahie-Wilson M.N. Ahlquist J.A. 2003 Hyperprolactinaemia due to macroprolactins: some progress but still a problem Clinical Endocrinology 58 683 685
3. Gibney J. Smith T.P. McKenna T.J. 2005 Clinical relevance of macroprolactin Clinical Endocrinology 62 633 643
4. Fahie-Wilson M. John R. Ellis A.R. 2005 Macroprolactin; high molecular mass forms of circulating prolactin Annals of Clinical Biochemistry 42 175 192
5. Hattori N. Ikekubo K. Ishihara T. Moridera K. Hino M. Kurahachi H. 1994 Correlation of antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin auto antibody European Journal of Endocrinology 130 438 445